Still Enriched By Partnership, Curis Faces Ongoing Risks In 2014
This article was originally published in The Pink Sheet Daily
The Lexington, Mass.-based oncology specialist seeks to resume enrollment in a Phase I trial halted after a patient death, while a revenue-generating drug partnered with Genentech could soon have a new competitor.
You may also be interested in...
Erivedge May Be The Gleevec Of Hedgehog Inhibitors
FDA approval of Curis/Genentech’s hedgehog inhibitor Erivedge validates the class, but basal cell carcinoma is only the ante; cancers exploit hedgehog signaling in a variety of ways yet to be elucidated.
Craig Venter Wants To Extend Your Life (And Own Your Data)
The onetime Celera CEO says his new attempt to centralize biological information into a massive database could lead to breakthroughs that extend the human life span. Behind that bold goal is a more mundane data-licensing strategy that, although not splashy, could still improve medicine.
Deals of the Week Takes Stock In M&A
Do high biotech share prices portend stock-heavy deal-making in lieu of all-cash transactions? Also, Biogen shares the risk with Eisai in an Alzheimer’s deal, while newly public Genocea and cell therapy specialist NeoStem both teamed with Harvard researchers.